Stage IV HER2-Positive Breast Cancer: Leftfootforward's Survivor Story

Patient Info: Leftfootforward, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain | Liver

Leftfootforward was diagnosed with Stage IIB HER2-positive breast cancer in 2010 and metastatic brain/liver disease in 2012; after systemic therapy, Gamma Knife, craniotomy for necrotic tissue, partial liver lobectomy, and resumed Herceptin, her latest scans showed no evidence of disease.

BreastCancer.org (ES)Read more →

Stage II HER2-Positive Breast Cancer: Frédérique's Survivor Story

Patient Info: Frédérique, Female, 40s | Stage II

Biomarkers: HER2-positive

Frédérique was listed as having complete remission after Herceptin/trastuzumab treatment for HER2-positive Stage II breast cancer.

Fondation ARCRead more →

HR-Positive Breast Cancer: Toni's Patient Story

Patient Info: Toni S, Female, 50s

Biomarkers: ER-positive or PR-positive; HER2-positive; triple-positive breast cancer

Toni completed chemotherapy, surgery, Kadcyla, and radiation for triple-positive breast cancer with lymph-node involvement and continued anastrozole to suppress estrogen.

BreastCancer.org (ES)Read more →

Breast Cancer: Greta's Survivor Story

Patient Info: Greta Tietze-Stein, Female, 50s

Greta completed breast-conserving surgery, chemotherapy, radiation, trastuzumab antibody therapy, and hormone therapy, and continued follow-up while managing fear of another finding and rebuilding life around family, faith, and self-care.

Krankheitserfahrungen.deRead more →

Breast Cancer: Dagmar's Patient Story

Patient Info: Dagmar Schiffer, Female, 50s

Dagmar had completed surgery, chemotherapy, and radiation and continued antibody therapy plus hormone therapy, while managing bone pain, fatigue, and daily-life adjustments.

Krankheitserfahrungen.deRead more →

BRCA1 Breast Cancer: Jasmin's Patient Story

Patient Info: Jasmin Nussing, Female, Under 40

Biomarkers: BRCA1 mutation

Jasmin completed major breast cancer treatment while continuing technical school, had BRCA1-related long-term risk management ahead, and required ongoing heart monitoring related to antibody/immunotherapy.

Krankheitserfahrungen.deRead more →

Hormone receptor-positive, HER2-positive breast cancer treatment interrupted by vaginal cuff dehiscence and bowel evisceration

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Hormone receptor-positive; HER2-positive

At 21 months after emergency repair, she was symptom-free with POP-Q stage 0; letrozole continued and T-DM1 was resumed 7 weeks after discharge, but long-term cancer response was not detailed.

PubMed CentralRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Doreen's Patient Story

Patient Info: Doreen, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Doreen had completed TCHP chemotherapy with a complete response before surgery and had undergone lumpectomy and radiation for Stage IIA triple-positive breast cancer.

The Patient StoryRead more →

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Glycogen-rich clear cell breast carcinoma: HER2-positive early-stage case with disease-free follow-up

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; HER2-positive; PR-negative; Ki-67 ~10%; intracytoplasmic glycogen confirmed

At 1-year follow-up, she had no evidence of breast cancer recurrence.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of HopeRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed CentralRead more →

Stage I Breast Cancer: Angela's Patient Story

Patient Info: Angela George, Female, 40s | Stage I

Biomarkers: Not explicitly reported; Herceptin was given

As of September 2025, Angela was approaching 5 years from her Stage I breast cancer diagnosis, had completed bilateral mastectomy, chemotherapy, Herceptin, and oophorectomy, and remained on daily estrogen-reducing medication with oncology visits every 6 months; the source does not explicitly state NED.

Cleveland ClinicRead more →

Stage I HER2-Positive Breast Cancer: Betty's Survivor Story

Patient Info: Betty, Female, 50s | Stage I

Biomarkers: HER2-positive

As of 2021, Betty was in remission after mastectomy and chemotherapy with Herceptin, while managing side effects such as hair loss, peripheral neuropathy, and weight changes.

Our Cancer StoriesRead more →

Stage IV HER2-Positive Breast Cancer: Kate's Survivor Story

Patient Info: Kate Watson, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Chest lymph nodes; spine; pelvis; femur

As of October 2019, Kate had been in remission for about 3 years with regular PET scans showing no evidence of active disease, while continuing monthly HER2-targeted maintenance treatment.

Cleveland ClinicRead more →